Dedicated to transforming the care of people living with Rare Genetic Disorders of Obesity

We’re focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger.


By targeting the MC4R pathway, we aim to develop therapeutics
for rare genetic disorders of obesity, including:

Proopiomelanocortin (POMC)
Deficiency Obesity
Leptin Receptor (LEPR)
Deficiency Obesity
Bardet-Biedl
syndrome (BBS)
Alström
syndrome
Prader-Willi
syndrome (PWS)
High-impact
Heterozygous Obesity

Our news

2019-12-05T08:00:00

Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes

2019-11-13T08:01:00

Rhythm Pharmaceuticals to Present at Stifel 2019 Healthcare Conference

2019-11-04T16:01:00

Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019